- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05105633
Extending the Time Window for Tenecteplase by Recanalization of Basilar Artery Occlusion in Posterior Circulation Stroke (POST-ETERNAL)
December 5, 2023 updated by: University of Melbourne
Extending the Time Window for Tenecteplase by Effective RecanalizatioN of bAsilar Artery occLusion in Patients With POSTerior Circulation Stroke (POST-ETERNAL)
Patients presenting to the emergency department with an acute ischemic stroke due to basilar artery occlusion within 24 hours of stroke onset will be assessed to determine their eligibility for randomization into the trial.
If the patient gives informed consent they will be randomised 50:50 using a central computerised allocation process to either standard of care (no intravenous thrombolytic treatment or intravenous alteplase 0.9mg/kg) or tenecteplase 0.25mg/kg before undergoing mechanical thrombectomy as required at treating clinician's discretion.
The trial is Multi-arm, Multi-stage, prospective, randomised, open-label, blinded endpoint (PROBE) design with seamless phase 2b/3 transition if the intermediate endpoint (recanalization without symptomatic intracerebral hemorrhage) is met in analysis of the first 202 patients.
Adaptive sample size re-estimation (Mehta and Pocock) will be performed when 240 patients have completed 3 month follow-up (minimum sample size 320, maximum sample size 688).
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
The study is a Multi-Arm Multi-Stage (MAMS), multiregional, multicentre, prospective, randomised, open-label, blinded endpoint (PROBE), controlled seamless phase 2b/3 trial (2 arm with 1:1 randomisation) with adaptive sample size recalculation in patients with stroke due to basilar artery occlusion.
Stage 1 will use the surrogate outcome of recanalization without symptomatic intracerebral hemorrhage (sICH) to establish whether proceeding to Stage 2 is warranted.
If results in the first n= 202 patients meet success criteria, the trial will seamlessly convert to a phase 3 design using modified Rankin scale 0-1 at 3 months as the primary outcome (minimum n=320 with interim sample size re-estimation at n=240, maximum sample n=688) using the Mehta and Pocock conditional power method.
Each regionally-based stratum will be pooled in the final analysis and analysed as a stratification by geographic region.
Randomisation of patients within each stratum will be stratified by the investigator's intention to treat with mechanical thrombectomy (or not) and the investigator's intention to treat with alteplase intravenous thrombolysis should the patient be randomised to the control group (or not).
Covariate adjusted minimum sufficient balance randomisation will then be applied to control for age, NIHSS and time from onset-to-randomisation (dichotomized as 0-6 hours vs 6-24 hours).
The primary objective of the study is to test the hypothesis that the thrombolytic tenecteplase (TNK, 0.25mg/kg) ± mechanical thrombectomy administered within 24 hours after symptoms onset, is superior to current best practice (alteplase, rtPA, 0.9mg/kg or standard care/no lysis ± mechanical thrombectomy) in achieving excellent functional outcome (mRS 0-1) or return to the premorbid modified Rankin Scale at 90 days in patients with acute ischemic stroke due to basilar artery occlusion.
Estimated study duration is 5 years.
Patients will participate in the trial for 12 months.
Study Type
Interventional
Enrollment (Estimated)
688
Phase
- Phase 2
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Fana Alemseged, MD, PhD
- Phone Number: +6193424424
- Email: Fana.Alemseged@unimelb.edu.au
Study Contact Backup
- Name: Amy McDonald, BN
- Phone Number: +6193424424
- Email: Amy.McDonald@mh.org.au
Study Locations
-
-
New South Wales
-
Bankstown, New South Wales, Australia
- Not yet recruiting
- Bankstown-Lidcombe Hospital
-
Contact:
- Megan Miller
-
Principal Investigator:
- Fintan O' Rourke
-
Newcastle, New South Wales, Australia
- Not yet recruiting
- John Hunter Hospital
-
Contact:
- Michelle Russell
-
Principal Investigator:
- Carlos Garcia Esperon
-
Sydney, New South Wales, Australia
- Not yet recruiting
- Liverpool Hospital
-
Contact:
- Megan Miller
-
Principal Investigator:
- Mark Parsons
-
-
Queensland
-
Gold Coast, Queensland, Australia
- Not yet recruiting
- Gold Coast Hospital
-
Contact:
- Berzenn Urbi
-
Principal Investigator:
- Peter Bailey
-
Woolloongabba, Queensland, Australia, 4102
- Recruiting
- Princess Alexandra Hospital
-
Principal Investigator:
- Michael Devlin
-
Contact:
- Carol Bendall
-
-
South Australia
-
Adelaide, South Australia, Australia
- Recruiting
- Royal Adelaide Hospital
-
Contact:
- Jennifer Cranefield
-
Principal Investigator:
- Timothy Kleinig
-
-
Victoria
-
Melbourne, Victoria, Australia
- Not yet recruiting
- Austin Hospital
-
Contact:
- Dennis Young
-
Principal Investigator:
- Vincent Thijs
-
Melbourne, Victoria, Australia
- Recruiting
- Royal Melbourne Hospital
-
Contact:
- Amy McDonald, BN
- Phone Number: +619342 4424
- Email: amy.mcdonald@mh.org.au
-
Principal Investigator:
- Bruce Campbell
-
Melbourne, Victoria, Australia
- Recruiting
- Box Hill Hospital
-
Contact:
- Tessa Busch
-
Principal Investigator:
- Philip Choi
-
Melbourne, Victoria, Australia
- Not yet recruiting
- Western Health
-
Contact:
- Sherisse Celestino
-
Principal Investigator:
- Tissa Wijeratne
-
Melbourne, Victoria, Australia
- Not yet recruiting
- Monash Health
-
Contact:
- Marie Veronic Hervet
-
Principal Investigator:
- Shaloo Singhal
-
Melbourne, Victoria, Australia
- Recruiting
- Alfred Health
-
Contact:
- Andrea Moore
-
Principal Investigator:
- Geoffrey Cloud
-
-
Western Australia
-
Murdoch, Western Australia, Australia, 6150
- Recruiting
- Fiona Stanley Hospital
-
Principal Investigator:
- Darshan Ghia
-
Contact:
- Phoebe Lee
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Patients presenting with posterior circulation ischemic stroke symptoms due to partial or complete basilar artery occlusion within 24 hours from symptom onset (or clinical deterioration/coma) or the time the patient was last known to be well.
- Patient's age is ≥18 years
- Presence of basilar artery occlusion, proven by CT Angiography or MR Angiography. Basilar artery occlusion is defined as 'potentially retrievable' occlusion at the basilar artery. This can be a partial or complete occlusion.
- Premorbid mRS ≤3 (independent function or requiring only minor domestic assistance and able to manage alone for at least 1 week).
- Local legal requirements for consent have been satisfied.
Exclusion Criteria:
- Intracerebral hemorrhage (ICH) or other diagnosis (e.g. tumour) identified by baseline imaging.
- Posterior circulation Acute Stroke Prognosis Early CT score (pc-ASPECTS) <7 on non-contrast CT, CT Angiography source images or DWI MRI.
- Significant cerebellar mass effect or acute hydrocephalus.
- Established frank hypodensity on non-contrast CT indicating subacute infarction.
- Bilateral extensive brainstem ischemia.
- Strong suspicion of underlying intracranial atherosclerotic disease (e.g diffuse arterial calcifications, basilar stenosis) or dissection which may require immediate neuro-interventional procedure with intracranial stenting and not benefit from intravenous thrombolysis at investigator's discretion.
- Pre-stroke mRS of ≥4 (indicating moderate to severe previous disability).
- Other standard contraindications to intravenous thrombolysis.
- Contraindication to imaging with contrast agents.
- Clinically evident pregnant women.
- Current participation in another research drug treatment protocol.
- Known terminal illness such that the patients would not be expected to survive a year.
- Planned withdrawal of care or comfort care measures.
- Any condition that, in the judgment of the investigator could impose hazards to the patient if study therapy is initiated or affect the participation of the patient in the study.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Intravenous tenecteplase (TNK)
Patients will receive intravenous tenecteplase (0.25mg/kg, maximum 25mg, administered as a bolus over 5-10 seconds).
|
Genetically modified tissue plasminogen activator at a dose of 0.25mg/kg given as an intravenous bolus over 5-10 seconds.
|
Active Comparator: Standard Care (which may include intravenous Alteplase)
Patients will receive standard of care (no intravenous thrombolytic treatment or intravenous alteplase 0.9mg/kg at the standard licensed dose of 0.9 mg/kg up to a maximum of 90mg, 10% as a bolus and the remainder as an infusion over 1 hour).
|
Patients will receive standard care which may include intravenous alteplase at the standard licensed dose of 0.9 mg/kg up to a maximum of 90mg, 10% as a bolus and the remainder as an infusion over 1 hour.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Modified Rankin Scale (mRS) 0-1 or return to baseline mRS at 90 days
Time Frame: 90 days
|
Modified Rankin Scale (mRS) 0-1 (no disability) or return to baseline mRS (if baseline premorbid mRS 2-3) at 90 days
|
90 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
All-cause mortality within 90 days
Time Frame: 90 days
|
All-cause mortality within 90 days
|
90 days
|
Modified Rankin Scale 0-2 or return to baseline mRS at 90 days
Time Frame: 90 days
|
Proportion of patients with Modified Rankin Scale 0-2 or return to baseline mRS at 90 days
|
90 days
|
Modified Rankin Scale 0-3 or return to baseline mRS at 90 days
Time Frame: 90 days
|
Proportion of patients with Modified Rankin Scale 0-3 or return to baseline mRS at 90 days
|
90 days
|
Ordinal analysis of the mRS at 90 days
Time Frame: 90 days
|
Ordinal analysis of the mRS, merging category 5-6, at 90 days
|
90 days
|
Early clinical improvement
Time Frame: 72 hours
|
Proportion of patients achieving early clinical improvement (reduction in acute - 72 hour NIHSS score of ≥8 or 72 hour NIHSS 0-1).
|
72 hours
|
Substantial reperfusion on initial digital subtraction angiography run prior to thrombectomy
Time Frame: Initial angiogram (day 0)
|
Proportion of patients with complete occlusion at baseline who achieve eTICI 2b/3 on initial digital subtraction angiography run prior to thrombectomy.
|
Initial angiogram (day 0)
|
Quality of Life assessment (EQ-5D) - at 90 days and 12 months
Time Frame: 90 days and 12 months
|
Quality of Life assessment (EQ-5D) - at 90 days and 12 months
|
90 days and 12 months
|
Symptomatic intracerebral hemorrhage (sICH)
Time Frame: 36 hours
|
Proportion of patients with sICH defined as parenchymal hemorrhage type 2 (PH2), subarachnoid hemorrhage, and/or intraventricular hemorrhage within 36 of treatment, combined with a neurological deterioration of ≥4 points on the NIHSS from baseline, or leading to death.
|
36 hours
|
Modified Rankin Scale (mRS) 5-6 at 90 days
Time Frame: 90 days
|
Proportion of patients with Modified Rankin Scale (mRS) 5-6 at 90 days (severe disability or death)
|
90 days
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Intermediate outcome (Stage 1): Partial or complete recanalization of the basilar artery without sICH
Time Frame: Initial angiogram (day 0)
|
Proportion of patients achieving partial or complete recanalization of the basilar artery on initial digital subtraction angiography (DSA) prior to thrombectomy or repeat CT Angiography (if DSA not performed) without symptomatic intracerebral hemorrhage (sICH).
Partial or complete recanalization is defined as reperfusion of ≥50% of the affected territory or absence of retrievable thrombus.
|
Initial angiogram (day 0)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Bruce Campbell, University of Melbourne
- Principal Investigator: Fana Alemseged, University of Melbourne
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
November 29, 2021
Primary Completion (Estimated)
August 1, 2026
Study Completion (Estimated)
December 1, 2026
Study Registration Dates
First Submitted
October 21, 2021
First Submitted That Met QC Criteria
October 21, 2021
First Posted (Actual)
November 3, 2021
Study Record Updates
Last Update Posted (Estimated)
December 6, 2023
Last Update Submitted That Met QC Criteria
December 5, 2023
Last Verified
December 1, 2023
More Information
Terms related to this study
Keywords
- Stroke
- Vascular Diseases
- Cardiovascular Diseases
- Nervous System Diseases
- ischemic stroke
- Central Nervous System Diseases
- Brain Diseases
- Cerebrovascular Disorders
- Molecular Mechanisms of Pharmacological Action
- Tissue Plasminogen Activator
- Tenecteplase
- Fibrin Modulating Agents
- basilar artery occlusion
Additional Relevant MeSH Terms
Other Study ID Numbers
- CT21028
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
Anonymized individual patient data will be uploaded to the Virtual Stroke Trials Archive 2 years after the publication of the primary manuscript.
Qualified investigators can access data after submission of a project proposal that has been approved by the VISTA steering committee.
IPD Sharing Time Frame
2 years after the publication of the primary manuscript.
IPD Sharing Access Criteria
Qualified investigators can access data after submission of a project proposal that has been approved by the VISTA steering committee.
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Basilar Artery Occlusion
-
Erik van der HoevenBASICS Study GroupUnknownStroke | Cerebrovascular Disorders | Basilar Artery Occlusion | Stroke of Basilar Artery | Basilar Artery Thrombosis | Basilar Artery EmbolismNetherlands, Germany, Brazil, Italy, Norway, Switzerland
-
The First Affiliated Hospital of University of...CompletedBasilar Artery Occlusion | Acute Cerebrovascular Accident | Stroke Due to Basilar Artery OcclusionChina
-
The First Affiliated Hospital of University of...RecruitingBasilar Artery Occlusion | Acute Cerebrovascular Accident | Stroke Due to Basilar Artery OcclusionChina
-
The First Affiliated Hospital of University of...RecruitingIntravenous Tenecteplase Plus EVT Versus EVT Alone on 4.5 to 24 Hours After Basilar Artery OcclusionBasilar Artery Occlusion | Acute Cerebrovascular Accident | Stroke Due to Basilar Artery OcclusionChina
-
Xinfeng LiuCompletedStroke Due to Basilar Artery Occlusion | Acute Cerebrovascular AccidentsChina
-
Beijing Tiantan HospitalRecruitingBasilar Artery Occlusion | Endovascular TreatmentChina
-
First Hospital of China Medical UniversityNot yet recruitingBasilar Artery Occlusion | Thrombectomy | Tenecteplase
-
Hopital FochRecruiting
-
University of Medicine and Pharmacy at Ho Chi Minh...UnknownStroke, Acute | Basilar Artery Occlusion
-
115 People's HospitalRecruitingBasilar Artery OcclusionVietnam
Clinical Trials on Tenecteplase
-
Kaiser PermanenteGenentech, Inc.TerminatedPleural EffusionUnited States
-
Huashan HospitalShanghai 10th People's Hospital; Shanghai East Hospital; The Second Affiliated... and other collaboratorsCompleted
-
Boehringer IngelheimTerminatedHeart ArrestGermany, Belgium, Sweden, France, Austria, Italy, Norway, Spain, Switzerland
-
Genentech, Inc.CompletedDysfunctional Central Venous Access Catheters
-
University Of PerugiaTerminated
-
The George InstituteUniversity of Calgary; Berry ConsultantsNot yet recruiting
-
Genentech, Inc.CompletedDysfunctional Central Venous Access Catheters
-
Genentech, Inc.CompletedDysfunctional Hemodialysis Catheters
-
General Hospital of Shenyang Military RegionCompleted
-
ProMedica Health SystemGenentech, Inc.CompletedIschemic StrokeUnited States